PAR — Paradigm Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall Cap
- AU$143.29m
- AU$135.35m
- AU$8.12m
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm climbs on clinical trial progress for osteoarthritis treatment
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Brief: Paradigm Biopharmaceuticals Receives Regulatory & Ethics Approvals For Para_OA_002 Clinical Trial
Brief: Paradigm Biopharmaceuticals Says Abby Macnish Niven Appointed Interim CFO
Brief: Paradigm Biopharmaceuticals Says Marco Polizzi Stepped Down As CEO
Brief: Paradigm Biopharmaceuticals Says Achieved Primary Endpoint In Para_Oa_008 Phase 2 Clinical Trial
Australia's Paradigm rises on positive update from osteoarthritis drug trial
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Brief: Paradigm Biopharmaceuticals Posts FY Revenue From Continuing Activities A$8.8 Million
Paradigm Biopharmaceuticals drops most in over 5 years on discounted placement
Brief: Paradigm Biopharmaceuticals Launches A$66M Capital Raising
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm Biopharmaceuticals surges on research partnership deal
Brief: Paradigm Biopharmaceuticals Partners With Nfl Alumni Health On Osteoarthritis Program
Brief: Paradigm Biopharmaceuticals Receives A$8.2 Million Research And Development Tax Incentive Refund
Brief: FDA Grants Fast Track Designation For Paradigm Biopharmaceuticals Phase III Osteoarthritis Program